Poster

Accelerating Advancement In Gene Therapy By Improving Downstream Purification Of Viral Vectors

Source: Thermo Fisher Scientific

By Orjana Terova, John Li, Jessica de Rooij, Pim Hermans, Alejandro Becerra and Frank Detmers; Thermo Fisher Scientific

Over the past decade, gene therapy applications and their importance in the biopharmaceutical industry have been increasing. The non-pathogenic adeno-associated virus (AAV) has emerged as the vector of choice for many therapies but purification of biologically active viral vectors for large-scale commercial use is a challenge. Thermo Fisher Scientific has developed  downstream purification solutions, enabling the scale-up of viral vector production.

VIRAL VECTOR PURIFICATION CHALLENGES

  • Multiple chromatography steps & concentration needed due to challenging feedstock
  • Long process development lead times
  • Cumulative yield losses with each unit operation

VIEW THE POSTER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: